Genetic diagnostics may be entering a new era where a single test can simultaneously reveal both DNA sequence variations and epigenetic modifications that cause disease. This convergence addresses a long-standing limitation in clinical genomics, where methylation analysis—critical for diagnosing certain rare disorders—has required separate, array-based testing alongside standard sequencing. Researchers validated that long-read sequencing platforms from Pacific Biosciences and Oxford Nanopore can accurately detect DNA methylation signatures directly from native DNA samples. Testing samples from individuals with pathogenic KMT2D variants, the team demonstrated that methylation profiles generated by long-read technologies matched the diagnostic accuracy of established array-based methods. Support vector machine classifiers trained on array data correctly identified all long-read samples, while the public EpigenCentral platform also validated the results across different sequencing approaches. This technical validation represents more than incremental improvement—it suggests clinical laboratories could consolidate two separate diagnostic workflows into one comprehensive analysis. The implications extend beyond operational efficiency to enhanced diagnostic capability, particularly for rare genetic disorders where methylation signatures serve as critical biomarkers. However, the study's scope remains limited to proof-of-concept validation with KMT2D variants, and broader clinical implementation will require extensive validation across diverse genetic conditions, cost-effectiveness analysis, and standardization of methylation calling algorithms across different long-read platforms.